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RESUMO 
0 artigo discute dois temas arms: 1) doen~a 
pulmonar induzida pela radioterapia nas suas 
diferentes apresenta~6es: pneumonite de radia~io 
classica e fibrose pulmonar e outras duas mais 
recentemente descritas, BOOP e alveolite linfodta-
ria bilateraL Sio discutidos os mecanismos patoee-
nicos, clinic:a e tratamento; 2) a patologia intersticial 
induzida por farmacos dtostaticos nas suas varias 
formas de apresenta~io. 
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ABSTRACT 
In Ibis paper two topics art adressed: 1) the 
radiation induced lunc injury in its possible forms: 
classical radiation pneumonitis and radiation 
fibrosis or two other newly recoenised sindromes 
BOOP and bilateral lymphodtic alveolitis. The 
mecanism and treatment are discussed; 2) the 
cytotocic drug-induced luna diseases and their 
pulmonary reaction patterns. 
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RADIATION-INDUCED L UNG INJURY 
Radiation-induced lung damage is a limiting 
factor for radiotherapy not only of primary lW1g 
tumors but also of those arising in the breast, medias-
tinum and chest wall, as well as for total body irradia-
tion in hematological malignancies. The risk and 
severity of pulmonary complications following 
irradiation are inlluenced by total dose, dose fractio-
nation, and the irradiated lung volume. The effects of 
radiation are increased by a prior course of radiothe-
rapy, by previOus or concomitant treatment w1th 
cytotoxic drugs, by pre-existing lung disease, by 
hyperoxia and by discont111uation of treatment with 
corticosteroids. For unilateral irradiation, total doses 
ofless than 30 Gy usually have lit11e effect, whereas 
radiographic changes are usual with doses exceeding 
40 Gy (9). Beside the classical well-recognised 
syndromes related to thoracic radiation that occur in 
the radiation field, i.e. radiation pneumonitis and 
radiation fibrosis, recently two other syndromes have 
been recognised, occurring outside the field of 
radiation: bronchiolitis obliterans organising pneu-
monia and bilateral lymphocytic alveol itis (2.8. 14.15). 
Mechanisms 
Recent data suggest that there ~rc two separate 
and distinct mechanisms involved: First, the classical 
radiation pneumonitis which automatically leads to 
pulmonary fibrosis. Here the primary damage is to 
pulmonary endothelial cells and type 11 pneumocytes 
by the generation of free radicals which damage cell 
membranes and DNA This results in alteration of 
surfactant and surfactant lipoproteins, as well as in 
local cytokine production and release of pro-fibrotic 
mediators ( 11 , 1 s). Second, the sporadic radiation 
pneumonitis, resulting in bilateral lymphocytic 
alveolitis or bronchiolitis obliterans organising 
pneumonia. Here the process is immunologically 
mediated, with increase in activated T-lymphocytes 
in bronchoalveolar lavage flu id suggestive of a 
hypersensitivity pneumonHis (I S). 
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Clinical features 
Radiation pneumonitis occurs one to six tnonths 
after completion of radiation therapy. It is characteri-
sed by non-productive cough, dyspnoea and fever. 
Characteristically, the radiological findings are 
confined to the fie ld of radiation and consist of hazy 
shadowing progressing to more dense consolidation, 
often with an air bronchot:.tram, limited with a sharp 
margin to the irradiated field. Radiation fibrosis is the 
end result of radiation pneumonitis, occurring six to 
twelve months after irradiation. The fibrosis may be 
mild and asymptomatic, and may be detected without 
being preceded by a clinical radiation pneumonitis. 
Broncboalveolar lavage may reveal in the field of 
irradiation, but also in the contralateral lung, an 
increase 111 lymphocytes (7.14,16). There have been 
several case reports on the development of bronchio-
litis obliterans organising pneumonia in irradjated 
pat1ents with breast cancer, developing from 6 to 17 
months after the completion of radiotherapy. with 
recurrent and migrating lung infiltrates outside the 
radiation field ( 1,2,8). 
T reatment 
In most cases, the disease spontaneously resolves 
and no treatment is needed. In symptomatic patients, 
corticosteroids are given. Although no controlled 
studies are available, there is strong clinical evidence 
oftheireftectiveness. Corticosteroids are also effecti-
ve in radiation-induced BOOP. Recurrence of radiati-
on pneumonitis as well as ofBOOP may occur after 
withdrawal of corticosteroids ( 1 ). 
DRUG-INDUCED LUNG DISEASES 
Pulmonary compl1cat1ons are frequent 111 the 
course of malignant disease. Drug-induced reactions 
should always be considered. One third of clinical 
articles published about drug-induced lung disease 
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are related to antineoplastic agents (3. 1 o). These 
include chemotherapeutic agents, most frequently 
implicated being bleomycin, methotrexate, cyclo-
phosphamide, busulphan, melphalan, mitomycin, 
chlorambucil, and nitrosoureas. Also antiandrogen 
agents such as nilutam1de and bicalutamide have 
been reported to mduce mterstitial pneumonitis 
and/or eosinophilic pneumoma. Recently, cytokines 
such as mterferon or GM-CSF have been added to the 
list. The following discussion is limited to drugs used 
m antmeoplastic therapy. 
Incidence and risk 
The incidence is difficu lt to estimate. The risk 
ranges from below 1% to 4% and higher. For some 
drugs the risk IS related to the cumulative amount of 
drug received (carmustine, bleomycin, cyclophospha-
lmde) Other drugs, for instance methotrexate, do not 
show such a dose relationship. The disease may 
develop after treatment pcnods varying from a few 
days to many years (5.6) 
Mechanisms 
Two major mechanisms are unplicated in drug-
mduced lung inJury F1rst, a direct tox1city, mediated 
through reactive oxygen metabolites by inducing 
lesions m the DNA, particularly m type ll pneumocy-
tes, or mterference w1th collagen metabolism. Impli-
cated for instance for bleomycin. Second, an immu-
nologically mediated hypersensitivity reaction. Cell 
mediated hypersensitivity can be tested on the basis 
or a lymphoblast transformation test of blood 
lymphocytes or a 1mgratron inhibition of blood 
leukocytes. These tests are not applied in routine 
d1agnosis, however Bronchoalveolar lavage may 
show a lymphocytic alveolttts with a CD8 predomi-
nance (exception methotrexate, here a CD4 predomi-
nance). Lung b1opsy may reveal poorly defined 
granuloma formation, hyperplastic type 11 pneumocy-
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tes, and lymphocytic or eosinophilic infiltration of 
septal and intraalveolar spaces (12). 
Pulmonary reaction patterns 
Although the clinical presentation is non-specific 
and rather uniform, there are several pulmonary 
reaction patterns to be discriminated (5,6,10, 17): 
- acute reversible cellular interstitial pneumonitis 
(methotrexate, nitutamide, bleomycin, chloram-
bucil, hydroxyurea, iphosphamide, interferon-
alpha, interleukin-2, GM-CSF) (10). 
- Interstitial pneumomtis with alveolar damage 
(bleomycin, cyclophosphamide, melphalan, 
mitomycin, nitrosourcas). Here SAL-neutrophi-
lia is present (13). 
- Pulmonary fibrosis (busulphan, bleomycin, 
cyclophosphamide, nitrosoureas) ( 13, 18). 
- Pulmonary eosinophilia (bleomycin, nilutami-
de, bicalutamide) (19) 
- BOOP (bleomycin). BOOP induced by bleomy-
cin is distmct1ve in that rad10graph1c mfiltrates 
are often round or stellate, and thus may mimic 
lung metastasis (4). 
Clinica l presentation and diagnosis 
The clinical presentatiOn is usually variable and 
non-specific, and so are the chest roentgenographic 
findings. The most common pattern is bilateral 
peripheral alveolar infiltrates, with or without a 
migratory component. Pulmonary function shows a 
restrict1ve pattern and a reduced diffusing capacity. 
Occasionally peripheral blood eosinophilia is noted. 
In the subacute cellular interstitial pnewnonitts, 
patients present with dyspnoea, cough and fever. 
Correct diagnosis of drug-induced lung disease is 
d1fficult and is based mainly on clinical grounds. 
Ideally, 5 criteria should be fu lfilled: 
- Definite exposure to the drug. 
- Consistent clinical picture. 
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- Careful exclusion of other possible causes 
(infection, pulmonary involvement by under-
lying malignancy, inhalational causes such as 
extrinsic allergic alveolitis). 
- Improvement of symptoms after withdrawal of 
the drug (although Improvement is less likely in 
drug-induced pulmonary fibrosis or alveolar 
damage). In some cases improvement occurs 
only once steroids are given. 
Symptoms should recur if the drug is re-admi-
nistered> Re-challenges raise several problems, 
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